United States · Funded startup
5 rounds we have observed, with the 6 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.
Follow Aerie Pharmaceuticals and see its new rounds in your feed.Start following
Funding summaryUpdated 31 Oct 2026
$254Mraised across 5 rounds since 2010, from 5 sources
Each circle is a round, placed by date and sized by amount. The line above is the running total.
From a historical funding recordSEC filing: $125M sold, first sale Sept 2014
No investor was named in the report.
Reported by biospace.comSEC filing: $15M sold, first sale Dec 2012
No investor was named in the report.
Reported by sec.govSEC filing: $15M sold, first sale Dec 2012
Reported by sec.govSEC filing: $41M sold, first sale Feb 2011
No investor was named in the report.
Reported by sec.govSEC filing: $5.3M sold, first sale Aug 2010
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
TPG
Deerfield
Sofinnova Investments
Alta Partners
Osage University Partners
Clarus VenturesFrom historical deal records. Wrong? Tell us.
Missing a round, or an investor who was in one? Tell us.
Aerie Pharmaceuticals's investors include TPG, Deerfield, Sofinnova Investments, Alta Partners and Osage University Partners, and 1 more on record.
Aerie Pharmaceuticals has raised $254M across 5 rounds since 2010.
Aerie Pharmaceuticals's most recent round was an Undisclosed round of $125M in Sept 2014.
Its most recent round, $125M in Sept 2014, is also its largest on record.
Aerie Pharmaceuticals's first round on record, in Mar 2011, was backed by TPG, Sofinnova Investments and Alta Partners and 2 others.
Aerie Pharmaceuticals's latest named round is an Undisclosed round, in Sept 2014.
Aerie Pharmaceuticals is based in the United States.
Search every investor by what they have actually funded, then narrow to your stage and market. Free.
United States ·